ENO1 and acute myeloid leukemia: Although the adverse risk AML patients recorded the lowest anti-ENO1 concentration (0.920, 0–36.90 ng/mL), this was not significantly different from the intermediate (7.34, 2.75–11.49) or favourable (1.07, 0–34.60) risk groups (p = 0.3080).